JAMA SURG:肝细胞癌根治性切除后晚期复发的危险因素及患者预后

2018-11-11 MedSci MedSci原创

肝细胞癌(HCC)肝切除术后的晚期复发(超过2年)通常被认为是新发癌症。JAMA SURG近期发表了一篇文章,研究肝癌根治性肝切除术后晚期复发的危险因素,模式及预后。

肝细胞癌(HCC)肝切除术后的晚期复发(超过2年)通常被认为是新发癌症。JAMA SURG近期发表了一篇文章,研究肝癌根治性肝切除术后晚期复发的危险因素,模式及预后。

作者回顾性分析了2001年1月至2015年12月在中国6家医院接受肝癌根治性肝切除术的患者。在切除术后2年内存活且无复发的734例患者中,303例患者出现晚期复发。研究的主要目的是评估晚期复发的危险因素及晚期复发患者的模式,治疗和长期预后情况。通过单变量和多变量Cox回归分析以确定晚期复发的独立危险因素。在纳入的734名患者中,652名(88.8%)为男性,平均年龄为51岁。中位随访时间78.0个月,303例患者(41.3%)出现晚期复发。多变量分析表明,男性,肝硬化,多发肿瘤,卫星结节,肿瘤大小超过5 cm,肉眼及微观血管侵犯是晚期复发的独立危险因素。303例晚期复发患者中,273例(90.1%)仅肝内复发,30例(9.9%)肝内和肝外复发,没有患者仅出现肝外复发。303例晚期复发的患者中有165例(54.5%)接受了治愈性治疗,包括再次切除,移植和局部消融。多因素Cox回归模型分析表明,肝硬化,门静脉高压,Child-Pugh B或C级,巴塞罗那临床肝癌B期和C期和以及后续治疗是晚期复发患者总生存的独立预后因素。

文章最后认为,HCC切除术后晚期复发与性别,肝硬化以及原发HCC的侵袭性肿瘤特征有关。手术2年后的监测应针对肝脏。术后监测增加了根治性治疗的可能,改善了晚期复发患者的生存。

原始出处:

Xin-Fei Xu, Hao Xing, et al. Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma A Multicenter Study From China. JAMA SURG. November 7 2018 doi: 10.1001/jamasurg.2018.4334

本文系梅斯医学(MedSci)原创编译整理,转载需授权!




版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1978762, encodeId=f91519e8762f4, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Apr 26 04:01:00 CST 2019, time=2019-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863398, encodeId=cca6186339813, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Dec 30 13:01:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692020, encodeId=0c7516920201b, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Dec 13 14:01:00 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586120, encodeId=7d5d15861207a, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Tue Nov 13 10:01:00 CST 2018, time=2018-11-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1978762, encodeId=f91519e8762f4, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Apr 26 04:01:00 CST 2019, time=2019-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863398, encodeId=cca6186339813, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Dec 30 13:01:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692020, encodeId=0c7516920201b, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Dec 13 14:01:00 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586120, encodeId=7d5d15861207a, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Tue Nov 13 10:01:00 CST 2018, time=2018-11-13, status=1, ipAttribution=)]
    2018-12-30 xjy02
  3. [GetPortalCommentsPageByObjectIdResponse(id=1978762, encodeId=f91519e8762f4, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Apr 26 04:01:00 CST 2019, time=2019-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863398, encodeId=cca6186339813, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Dec 30 13:01:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692020, encodeId=0c7516920201b, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Dec 13 14:01:00 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586120, encodeId=7d5d15861207a, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Tue Nov 13 10:01:00 CST 2018, time=2018-11-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1978762, encodeId=f91519e8762f4, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Apr 26 04:01:00 CST 2019, time=2019-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863398, encodeId=cca6186339813, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Dec 30 13:01:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692020, encodeId=0c7516920201b, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Dec 13 14:01:00 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586120, encodeId=7d5d15861207a, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Tue Nov 13 10:01:00 CST 2018, time=2018-11-13, status=1, ipAttribution=)]
    2018-11-13 jeanqiuqiu

相关资讯

2018 ESMO临床实践指南:肝细胞癌的诊断,治疗和随访

2018年10月,欧洲肿瘤内科学会(ESMO)发布了肝细胞癌的诊断,治疗和随访指南,文章主要内容涉及肝细胞癌的发病率和流行病学,疾病监测,诊断以及病例/分子生物学诊断,分期和风险评估,干细胞癌的临床管理和随访等。

Hepatol Res:立体定向放射治疗对那些没有资格进行切除或消融治疗的小肝细胞癌患者有效

立体定向放射治疗对那些没有资格进行切除或消融治疗的小肝细胞癌患者有效。

J Hepatol:在抗病毒治疗期间,ALT水平正常与慢性乙型肝炎患者肝脏事件的风险降低有关

接受核苷酸类似物治疗的患者,在获得正常的ALT水平后,肝脏相关事件发生的风险降低。

CLIN CANCER RES:Refametinib联合Sorafenib治疗RAS突变肝细胞癌

Refametinib 是一种口服MEK抑制剂,与 Sorafenib联合使用治疗RAS突变的肝细胞癌(HCC)的患者时具有抗肿瘤活性。CLIN CANCER RES近期发表了一篇文章,报道了Refametinib单药以及Refametinib 联合Sorafenib治疗RAS突变无法切除或转移性HCC 患者的疗效。

J Hepatol:肝脏僵硬测量可检测出晚期肝纤维化,并可预测丙型肝炎相关事件

在初级保健卫生系统管理的CHC,由LSM所确定的晚期纤维化的流行率显著的,且与医院队列的流行率相当。此外,本研究支持将LSM作为CHC人群的社区筛选工具。

J Hepatol:社区保健中心CHC患者肝脏硬度增加的流行率和探究晚期肝脏疾病、肝脏相关事件的预测因素

在社区保健中心由LSM所确定的晚期纤维化的比率为16.5%,并且社区保健中心由LSM确定的肝硬化比率与医院队列相当。